Details of Disease

General Information of Disease (ID: DIS0AFR7)

Disease Name	Insomnia
Synonyms	DSPS; DSPD; delayed sleep phase syndrome, susceptibility to; delayed sleep phase disorder, susceptibility to; insomnia (disease); insomnia; Sleeplessness
Disease Class	7A00-7A0Z: Insomnia
Definition	A sleep disorder characterized by difficulty in falling asleep and/or remaining asleep.
Disease Hierarchy	DIS3JP1U: Sleep disorder DIS6ZC3X: Brain disease DIS0AFR7: Insomnia
ICD Code	ICD-11 ICD-11: 7A00-7A0Z
Disease Identifiers	MONDO ID MONDO_0013600 MESH ID D007319 UMLS CUI C0917801 MedGen ID 214589 HPO ID HP:0100785 SNOMED CT ID 193462001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 42 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amobarbital	DM0GQ8N	Approved	Small molecular drug	[1]
Aprobarbital	DMOWK6B	Approved	Small molecular drug	[2]
Barbital	DMJ8NMC	Approved	Small molecular drug	[3]
Butabarbital	DMC5AST	Approved	Small molecular drug	[4]
Butethal	DM7JHX0	Approved	Small molecular drug	[5]
Carphenazine	DMHTB31	Approved	Small molecular drug	[6]
Chloral hydrate	DMEOSTQ	Approved	Small molecular drug	[7]
Citalopram	DM2G9AE	Approved	Small molecular drug	[8]
Daridorexant	DMPMVRL	Approved	NA	[9]
Diphenhydramine	DMKQTBA	Approved	Small molecular drug	[10]
Doxepin	DMPI98T	Approved	Small molecular drug	[11]
Estazolam	DMZGXUM	Approved	Small molecular drug	[12]
Eszopiclone	DM8RZ9H	Approved	Small molecular drug	[13]
Ethchlorvynol	DM53IP1	Approved	Small molecular drug	[14]
Ethinamate	DMK57GB	Approved	Small molecular drug	[15]
Flunitrazepam	DMGR5Z3	Approved	Small molecular drug	[16]
Flurazepam	DMAL4G0	Approved	Small molecular drug	[17]
Gaboxadol	DMI53FU	Approved	Small molecular drug	[18]
Glutethimide	DMGE0CW	Approved	Small molecular drug	[19]
Indiplon	DMOPGHQ	Approved	Small molecular drug	[20]
KI-0806	DMOF92I	Approved	NA	[6]
Lemborexant	DM3DGSG	Approved	NA	[21]
Melatonin	DMKWFBT	Approved	Small molecular drug	[22]
Methyprylon	DMBW7VH	Approved	Small molecular drug	[23]
NABILONE	DMVRYT2	Approved	Small molecular drug	[6]
Nitrazepam	DMEGIQ6	Approved	Small molecular drug	[24]
obeticholic acid	DM3Q1SM	Approved	Small molecular drug	[25]
Paraldehyde	DMOC1BX	Approved	Small molecular drug	[6]
Pentobarbital	DMFNH7L	Approved	Small molecular drug	[26]
Prazepam	DMEWC7N	Approved	Small molecular drug	[27]
Propiomazine	DMKY8V1	Approved	Small molecular drug	[28]
Quazepam	DMY4D87	Approved	Small molecular drug	[29]
Ramelteon	DM7IW9J	Approved	Small molecular drug	[30]
Secobarbital	DM14RF5	Approved	Small molecular drug	[31]
Suvorexant	DM0E6S3	Approved	Small molecular drug	[32]
Tasimelteon	DMLOQ1V	Approved	Small molecular drug	[33]
Temazepam	DM02A65	Approved	Small molecular drug	[34]
Triazolam	DMETYK5	Approved	Small molecular drug	[35]
Triclofos Sodium	DMGNYNO	Approved	Small molecular drug	[6]
Zaleplon	DMGFWSM	Approved	Small molecular drug	[36]
Zolpidem	DMWOSKJ	Approved	Small molecular drug	[37]
Zopiclone	DMPI6Z0	Approved	Small molecular drug	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 42 Drug(s)

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ITI-007	DMUQ1DO	Phase 3	Small molecular drug	[39]
EVT-201	DMQGBM1	Phase 2	NA	[40]
LY-2624803	DMTPQUA	Phase 2	NA	[41]
MK-3697	DM347TQ	Phase 2	NA	[42]
MK-6096	DM1V78I	Phase 2	Small molecular drug	[43]
Neu-P11	DMIQDFW	Phase 2	Small molecular drug	[44]
PD-200390	DMPW28M	Phase 2	Small molecular drug	[45]
SB-649868	DMYLBOU	Phase 2	Small molecular drug	[46]
Pipamperone	DMINSOX	Phase 1/2	Small molecular drug	[47]
INT-0020	DMYJXD1	Phase 1	NA	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Methaqualone	DMW9NY0	Withdrawn from market	Small molecular drug	[6]
Almorexant	DMQALR5	Terminated	Small molecular drug	[50]
SL-18.1616	DMI1WNF	Terminated	NA	[51]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TTA-A8	DMWZCIF	Preclinical	Small molecular drug	[49]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AB-1003	DMCHM0D	Investigative	NA	[52]
CHOLINE	DM5D9YK	Investigative	Small molecular drug	[53]
JNJ-10397049	DMZ8M0K	Investigative	Small molecular drug	[54]
NGD 96-3	DMWD7I3	Investigative	NA	[55]
NV.TLM.10	DM1PFEA	Investigative	NA	[52]
SC-72393	DMREMUJ	Investigative	NA	[52]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 16 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACTG1	TTGAZF9	Strong	Biomarker	[56]
ADORA2A	TTM2AOE	Strong	Genetic Variation	[57]
ADRA2A	TTWG9A4	Strong	Genetic Variation	[58]
FBXO3	TTUX14L	Strong	Genetic Variation	[59]
GAD1	TTKGEP3	Strong	Biomarker	[60]
HCRTR1	TT60Q8D	Strong	Biomarker	[61]
HCRTR2	TT9N02I	Strong	Biomarker	[61]
MAP3K10	TT9FN4J	Strong	Biomarker	[62]
MTNR1A	TT0WAIE	Strong	Biomarker	[63]
MTNR1B	TT32JK8	Strong	Biomarker	[63]
OAT	TTTSCQ2	Strong	Biomarker	[64]
PRNP	TTY5F9C	Strong	Biomarker	[65]
SDHD	TTVH9W8	Strong	Biomarker	[66]
SLC17A5	TTFSUIA	Strong	Biomarker	[67]
SLC6A4	TT3ROYC	Strong	Genetic Variation	[68]
TST	TT51OTS	Strong	Biomarker	[69]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 DTT(s)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
DDAH1	DEY0TQC	Strong	Biomarker	[70]
NDUFS7	DEIW03B	Strong	Genetic Variation	[71]
------------------------------------------------------------------------------------

This Disease Is Related to 40 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GABRB3	OT80C3D4	Limited	Biomarker	[72]
LMX1B	OTM8145D	Limited	Biomarker	[73]
SIAE	OTDQUESH	Limited	Genetic Variation	[74]
ACOT7	OT7C68YV	Strong	Biomarker	[56]
ACTBL2	OTD6B81U	Strong	Biomarker	[56]
ACTG2	OTRDWUO0	Strong	Biomarker	[56]
AMT	OTQYEWZQ	Strong	Biomarker	[75]
ARSI	OTIANNWW	Strong	Biomarker	[76]
CD200R1	OT65Q9M6	Strong	Biomarker	[61]
CENPJ	OTZCQZN5	Strong	Biomarker	[77]
CLOCK	OTNEOJY7	Strong	Altered Expression	[78]
DDAH2	OT8Q40G2	Strong	Biomarker	[70]
EBPL	OT59J1GY	Strong	Biomarker	[79]
FHL5	OT6C00Z1	Strong	Biomarker	[56]
FREM3	OTXF7MOZ	Strong	Genetic Variation	[80]
GSC	OT4DH7PR	Strong	Biomarker	[81]
GTF2H5	OTRL219S	Strong	Biomarker	[82]
IARS1	OT9WXH5N	Strong	Altered Expression	[83]
IGSF6	OT5TUH02	Strong	Biomarker	[84]
MADD	OTUFYVGG	Strong	Biomarker	[85]
MARCHF11	OTODNSYN	Strong	Biomarker	[86]
MOCOS	OT0TL3Q5	Strong	Biomarker	[87]
MPST	OTCDPH5D	Strong	Biomarker	[62]
MSTO1	OT37XCNP	Strong	Biomarker	[62]
NDUFS4	OTJKUYEE	Strong	Genetic Variation	[88]
PDC	OT1UUVYY	Strong	Biomarker	[89]
PER3	OTVKYVJA	Strong	Genetic Variation	[90]
PIGR	OT6GLSUL	Strong	Altered Expression	[91]
PLEKHM2	OT4ZYV73	Strong	Biomarker	[85]
POTEM	OT7L2HGH	Strong	Biomarker	[56]
PPP2R3C	OT7E6V9B	Strong	Biomarker	[85]
PRLHR	OT1THGOP	Strong	Genetic Variation	[92]
PSG5	OTHTU98X	Strong	Biomarker	[93]
REM1	OTUXL0HC	Strong	Altered Expression	[94]
ROM1	OTE7H0YV	Strong	Biomarker	[95]
SERPINA3	OT9BP2S0	Strong	Biomarker	[56]
SMCP	OTXKY794	Strong	Biomarker	[87]
STAC	OTRVBSLR	Strong	Biomarker	[96]
TMED9	OTYGAQS0	Strong	Biomarker	[97]
TPPP	OTCFMSUF	Strong	Biomarker	[97]
------------------------------------------------------------------------------------


⏷ Show the Full List of 40 DOT(s)

References

1	Drug information of Amobarbital, 2008. eduDrugs.
2	Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8.
3	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7137).
5	Drug information of Soneryl, 2008. eduDrugs.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7	Chloral hydrate. 2017 Jan 23. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
8	Citalopram FDA Label
9	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214985.
10	Diphenhydramine FDA Label
11	Doxepin FDA Label
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7550).
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7429).
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7180).
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7325).
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4360).
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7188).
18	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4322).
19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7192).
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4221).
21	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 224).
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7238).
24	Drug information of Nitrazepam, 2008. eduDrugs.
25	Nuclear receptors and lipid physiology: opening the X-files. Science. 2001 Nov 30;294(5548):1866-70.
26	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5480).
27	Prazepam FDA Label
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7284).
29	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7288).
30	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1356).
31	Secobarbital FDA Label
32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2890).
33	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7300).
35	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7313).
36	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4345).
37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4348).
38	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7430).
39	ClinicalTrials.gov (NCT02469155) A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment.
40	ClinicalTrials.gov (NCT00380003) Efficacy Study of EVT 201 to Treat Insomnia. U.S. National Institutes of Health.
41	ClinicalTrials.gov (NCT00784875) An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia. U.S. National Institutes of Health.
42	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033199)
43	ClinicalTrials.gov (NCT01021852) Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011). U.S. National Institutes of Health.
44	ClinicalTrials.gov (NCT01489969) Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients. U.S. National Institutes of Health.
45	Synthesis and in vivo evaluation of bicyclic gababutins. Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4.
46	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4461).
47	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 92).
48	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034015)
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7724).
50	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2886).
51	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014349)
52	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
53	Choline FDA Label
54	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1701).
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
56	Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.J Psychopharmacol. 2020 Mar;34(3):326-335. doi: 10.1177/0269881119882854. Epub 2019 Oct 23.
57	The Impact of Genetic Variations in ADORA2A in the Association between Caffeine Consumption and Sleep.Genes (Basel). 2019 Dec 6;10(12):1021. doi: 10.3390/genes10121021.
58	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.Mov Disord. 2019 Dec;34(12):1839-1850. doi: 10.1002/mds.27845. Epub 2019 Sep 10.
59	Validity, potential clinical utility, and comparison of consumer and research-grade activity trackers in Insomnia Disorder I: In-lab validation against polysomnography.J Sleep Res. 2020 Feb;29(1):e12931. doi: 10.1111/jsr.12931. Epub 2019 Oct 18.
60	The Effect of Melatonin Upon Postacute Withdrawal Among Males in a Residential Treatment Program (M-PAWS): A Randomized, Double-blind, Placebo-controlled Trial.J Addict Med. 2018 May/Jun;12(3):201-206. doi: 10.1097/ADM.0000000000000386.
61	Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8.
62	Associations between traumatic brain injury from intimate partner violence and future psychosocial health risks in women.Compr Psychiatry. 2019 Jul;92:13-21. doi: 10.1016/j.comppsych.2019.05.001. Epub 2019 May 14.
63	Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.J Mol Neurosci. 2011 Oct;45(2):304-8. doi: 10.1007/s12031-011-9522-6. Epub 2011 Apr 28.
64	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment.Subst Use Misuse. 2019;54(10):1589-1598. doi: 10.1080/10826084.2018.1552298. Epub 2019 May 26.
65	A case of dementia with PRNP D178Ncis-129M and no insomnia.Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):415-7. doi: 10.1097/WAD.0b013e3181ae3a76.
66	Cognitive behaviour therapy for insomnia and depression: qualitative reflections from older adults who participated in a randomised controlled trial.Aging Ment Health. 2020 Jun;24(6):932-938. doi: 10.1080/13607863.2019.1571013. Epub 2019 Feb 12.
67	Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder.Curr Alzheimer Res. 2017;14(3):309-316. doi: 10.2174/1567205013666161108104703.
68	The Association between Serotonin Transporter Polymorphism, Platelet Serotonin Concentration and Insomnia in Non-Depressed Veterans with Posttraumatic Stress Disorder.Psychiatr Danub. 2019 Mar;31(1):78-87. doi: 10.24869/psyd.2019.78.
69	Insomnia Patients With Objective Short Sleep Duration Have a Blunted Response to Cognitive Behavioral Therapy for Insomnia.Sleep. 2017 Jan 1;40(1):zsw012. doi: 10.1093/sleep/zsw012.
70	Procyanidin B2 from lotus seedpod regulate NO/ADMA/DDAH pathway to treat insomnia in rats.Fundam Clin Pharmacol. 2019 Oct;33(5):549-557. doi: 10.1111/fcp.12462. Epub 2019 Apr 16.
71	Prevalence of sleep disturbances among head and neck cancer patients: A systematic review and meta-analysis.Sleep Med Rev. 2019 Oct;47:62-73. doi: 10.1016/j.smrv.2019.06.003. Epub 2019 Jun 21.
72	Functional characterization of the new human GABA(A) receptor mutation beta3(R192H).Hum Genet. 2002 Aug;111(2):154-60. doi: 10.1007/s00439-002-0766-7. Epub 2002 Jul 16.
73	Nail-patella syndrome with an emphasis on the risk of renal and ocular findings.Pediatr Dermatol. 2010 Jan-Feb;27(1):95-7. doi: 10.1111/j.1525-1470.2009.01051.x.
74	The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study.Psychol Health Med. 2019 Mar;24(3):333-343. doi: 10.1080/13548506.2018.1529325. Epub 2018 Oct 4.
75	Effects of Anma therapy (Japanese massage) on health-related quality of life in gynecologic cancer survivors: A randomized controlled trial.PLoS One. 2018 May 3;13(5):e0196638. doi: 10.1371/journal.pone.0196638. eCollection 2018.
76	New Method for Insomnia Mongolian Mind-Body Interactive Psychotherapy in the Assessment of Chronic Insomnia: A Retrospective Study.Adv Ther. 2018 Jul;35(7):993-1000. doi: 10.1007/s12325-018-0726-9. Epub 2018 Jun 19.
77	Specific insomnia symptoms and self-efficacy explain CPAP compliance in a sample of OSAS patients.PLoS One. 2018 Apr 4;13(4):e0195343. doi: 10.1371/journal.pone.0195343. eCollection 2018.
78	Sleep Disturbance and Altered Expression of Circadian Clock Genes in Patients With Sudden Sensorineural Hearing Loss.Medicine (Baltimore). 2015 Jul;94(26):e978. doi: 10.1097/MD.0000000000000978.
79	Attentional bias towards sleep-related stimuli in insomnia disorder: a behavioural and ERP study.J Sleep Res. 2018 Jun;27(3):e12652. doi: 10.1111/jsr.12652. Epub 2018 Jan 10.
80	A study of the combined effects of the EHD3 and FREM3 genes in patients with major depressive disorder.Am J Med Genet B Neuropsychiatr Genet. 2012 Apr;159B(3):336-42. doi: 10.1002/ajmg.b.32033. Epub 2012 Feb 15.
81	Insomnia-perchance a dream? Results from a NREM/REM sleep awakening study in good sleepers and patients with insomnia.Sleep. 2018 May 1;41(5). doi: 10.1093/sleep/zsy032.
82	The Mechanism of Compound Anshen Essential Oil in the Treatment of Insomnia Was Examined by Network Pharmacology.Evid Based Complement Alternat Med. 2019 Jun 4;2019:9241403. doi: 10.1155/2019/9241403. eCollection 2019.
83	The Association Between Insomnia and Sleep Duration in Adults With Attention-Deficit Hyperactivity Disorder: Results From a General Population Study.J Clin Sleep Med. 2018 Mar 15;14(3):349-357. doi: 10.5664/jcsm.6976.
84	The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model.Sleep. 2020 Mar 12;43(3):zsz241. doi: 10.1093/sleep/zsz241.
85	Integrative analysis of genome-wide association study and brain region related enhancer maps identifies biological pathways for insomnia.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:180-185. doi: 10.1016/j.pnpbp.2018.05.026. Epub 2018 Jun 6.
86	Longitudinal trends in disaster-related insomnia among Fukushima nuclear plant workers: the Fukushima Nuclear Energy Workers' Support Project study.Sleep. 2019 May 1;42(5):zsz043. doi: 10.1093/sleep/zsz043.
87	Relationship between Sleep Disorders and Health Related Quality of Life-Results from the Georgia SOMNUS Study.Int J Environ Res Public Health. 2018 Jul 26;15(8):1588. doi: 10.3390/ijerph15081588.
88	Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13030. Epub 2017 Oct 12.
89	Expression and Purification of Delta Sleep-Inducing Peptide Fused with Protein Transduction Domain and Human Serum Albumin in Pichia pastoris.Protein Pept Lett. 2017;24(7):668-675. doi: 10.2174/0929866524666170426113022.
90	Associations between period 3 gene polymorphisms and sleep- /chronotype-related variables in patients with late-life insomnia.Chronobiol Int. 2017;34(5):624-631. doi: 10.1080/07420528.2017.1287083. Epub 2017 Feb 27.
91	Personalized goal for insomnia and clinical response in advanced cancer patients.Support Care Cancer. 2020 Mar;28(3):1089-1096. doi: 10.1007/s00520-019-04912-z. Epub 2019 Jun 12.
92	Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.Support Care Cancer. 2018 Jul;26(7):2471-2477. doi: 10.1007/s00520-018-4087-3. Epub 2018 Feb 12.
93	The Relationship Between PSG and Morning/Evening Emotional Parameters in Patients With Insomnia Disorder and Good Sleepers.Front Psychol. 2019 Jan 10;9:2712. doi: 10.3389/fpsyg.2018.02712. eCollection 2018.
94	Brain-derived neurotrophic factor is a biomarker for subjective insomnia but not objectively assessable poor sleep continuity.J Psychiatr Res. 2019 Mar;110:103-109. doi: 10.1016/j.jpsychires.2018.12.020. Epub 2019 Jan 4.
95	Analysis of patients' sleep disorder after total knee arthroplasty-A retrospective study.J Orthop Sci. 2019 Jan;24(1):116-120. doi: 10.1016/j.jos.2018.07.019. Epub 2018 Aug 23.
96	Stabilising sleep for patients admitted at acute crisis to a psychiatric hospital (OWLS): an assessor-blind pilot randomised controlled trial.Psychol Med. 2018 Jul;48(10):1694-1704. doi: 10.1017/S0033291717003191. Epub 2017 Nov 7.
97	The Effect of Insomnia on Cortical Excitability in Patients With Generalized Anxiety Disorder.Front Psychiatry. 2019 Jan 10;9:755. doi: 10.3389/fpsyt.2018.00755. eCollection 2018.